
FDA Clears GSK’s AREXVY for Adults 50-59: Expanded RSV Vaccine Use
GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted approval for AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) to prevent RSV lower respiratory…












